Author

Regina M. Myers

Children's Hospital of PhiladelphiaORCID 0000-0002-2542-2061Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Stephan A. GruppiD· 2 shared Alexandra NeeseriD· 1 shared Allison Barz LeahyiD· 1 shared Anna M. RomanoviD· 1 shared Ash A. AlizadehiD· 1 shared Astraea Jager· 1 shared Austin Cozzone· 1 shared Beatriz Goncalves· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

Stephan A. GruppORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioengineeringNature Biomedical EngineeringPeer-reviewedAug 25, 2025

Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells

Tomasz M. Grzywa, Alexandra Neeser, Ranjani Ramasubramanian…·Darrell J. Irvine

This study develops a method to generate optimized peptide ligands for CAR-T cell restimulation, demonstrating enhanced expansion and memory development in preclinical models.

8 citations

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologyNature CommunicationsPeer-reviewedApr 23, 2025

IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell acute lymphoblastic leukemia

Pablo Domizi, Jolanda Sarno, Astraea Jager…·Kara Lynn Davis

This study identifies IKAROS as a factor associated with antigen escape in B-ALL, showing that low IKAROS levels lead to reduced B-cell antigen expression and resistance to CD19- and CD22-targeted therapies.

22 citationstop 2%

humanbulk RNA-seq

𝕏 PostBluesky